KRECE . PRECISION LONGEVITY

Partnerships . English

Partnerwith KRECE . Spain and the EU first

KRECE is the Spanish language editorial reference on longevity, peptides and clinical grade supplementation: 580 published articles, every intervention graded N0 to N5, positions on the record. This page is for manufacturers and brands. Two tracks are open. One is deliberately closed.

580published articles, all evidence graded
N0 to N5evidence pyramid on every intervention
ES + EUoperating base . LATAM and Caribbean mid term
1 doorhq@krece.io . founder led, 30 years technical sales
01 . Editorial first

Who you would partner with

KRECE is an editorial publication before it is anything else. 580 published articles, each one graded on our N0 to N5 evidence pyramid, each one closing with a position we sign. The method is public: Editorial Policy and Methodology. The catalog is public too: the evidence catalog.

Our readers are where you want to sell. Spain is the first market; Mexico, Argentina, Colombia and the US Hispanic market follow. In Spanish, no one else maintains an evidence graded longevity corpus at this depth. That is the moat.

Structure built for two continents. KRECE LLC (Wyoming) as holding, operating base in Spain, an operational foothold in Paraguay for Latin America. Founder led: Ignacio Rubio, 30 years of technical sales.

Commerce is subordinate to editorial criteria. That is the asset you would be partnering with, and it is protected by design: see the firewall in section 05 before you write.

02 . Priority track

Our own supplement line, manufactured by you

We are building KRECE brand clinical grade supplements, manufactured by third parties. We bring the specification: evidence driven formulation, documented active doses, nothing hidden behind a blend. You bring certified manufacturing, in Spain or the EU. What we require:

  1. GMP certified facility, EU based, Spain preferred, with an audit trail we can inspect.
  2. Batch level third party CoAs: identity, potency, contaminants and heavy metals. Per batch, not per product line.
  3. EU compliant ingredient dossiers: EFSA claim awareness and Novel Food status resolved before quoting, not after.
  4. Formulation to spec: no proprietary blends, no cosmetic dosing, no ingredient substitutions without written sign off.
  5. Staged MOQs: we scale with demand. Partners who need warehouse sized first orders are not a fit.
hq@krece.ioSuggested subject: Supplier Inquiry KRECE · manufacturers and private label
Write now
03 . Second track

Distribution power in Spain and the EU

For established brands with strong complementary products: clinical grade supplements and cosmeceuticals with data. If you want distribution power in Spain and the EU, we bring founder led technical sales, regulatory navigation in Spain and the EU, market knowledge across Spanish speaking markets, and adjacency to an editorial ecosystem that is never for sale. Mid term option: Latin America and the Caribbean through our operating base, when the Spanish foundation justifies it.

Before we talk, we ask for four things: finished product, the primary evidence behind it, documented active doses, and HPLC or equivalent CoAs. If the data holds, the conversation is fast.

hq@krece.ioSuggested subject: Partnership Inquiry KRECE · brands and distribution
Write now
04 . Closed track

What we are not taking

Peptides, commercially: no. We publish the deepest peptide coverage in Spanish and that does not change. But sourcing or distributing peptides is closed for now: since late 2025 the FDA has issued wave after wave of warning letters to research use only peptide suppliers marketed for human use, dozens of letters including 30 in a single day in March 2026, with major vendors shutting down voluntarily. Building a consumer facing peptide supply chain under that enforcement climate is a risk we will not take, and we will not help a partner take it either. When the regulatory picture changes, this section changes.

Paid editorial
Reviews, rankings or links in exchange for money: never. Sponsorships exist, labeled as such, and never touch a conclusion.
Network and MLM models
Multi level structures and referral pyramids are incompatible with an evidence brand. No exceptions.
Proprietary blends
Formulas that hide underdosing behind a blend name do not enter our catalog and do not enter a deal.
Products without primary evidence
If the data does not exist, neither does the conversation. Our public bar is documented evidence, graded N0 to N5.
05 . Non negotiable

The editorial firewall

A commercial agreement never buys editorial position or coverage. Partnership decisions and coverage decisions run on separate criteria, and both are traceable to the same public methodology. If KRECE distributes a product in a category we also cover, the piece discloses it. If that firewall is a problem for your plan, we are not your partner. The full rule set lives in our Editorial Policy and our Philosophy.

06 . One door

How to start

One address: hq@krece.io. Use the subject that matches your case and include four things in the first email:

  1. Company and product line, with the markets where you sell today.
  2. Certifications: GMP, CoAs, dossiers. Whatever exists, attached or linked.
  3. What you want from Spain and the EU, and whether Latin America matters to your plan.
  4. Timeline and volumes you have in mind. Honest numbers beat big ones.
hq@krece.ioSuggested subject: Supplier Inquiry KRECE · manufacturers and private label
Write now
hq@krece.ioSuggested subject: Partnership Inquiry KRECE · brands and distribution
Write now

You will deal directly with the founder. We reply to what qualifies, in English or Spanish, within a few business days. En español: Colabora con KRECE. Equity conversations live on their own page: Investors.

Strong product, real data: talk to ushq@krece.io . we read everything, we answer what qualifies
Índice editorial · Más de 500 análisis con evidencia
Ver archivo completo